Chiradoni Thungappa Satheesh, Rakesh Taran, Jitendra Kumar Singh, Shanti Prakash Shrivastav, Nikunj K Vithalani, Kalyan Kusum Mukherjee, Rajnish Vasant Nagarkar, Tanveer Maksud, Ajay Omprakash Mehta, Krishnan Srinivasan, Mummaneni Vikranth, Satish Ramkrishna Sonawane, Ateeq Ahmad, Saifuddin Sheikh, Shoukath M Ali, Ronak Patel, Mahesh Paithankar, Lav Patel, Anil Rajani, Deepak Bunger, Alok Chaturvedi, Imran Ahmad
BACKGROUND: A novel nanosomal paclitaxel lipid suspension (NPLS), free from Cremophor EL (CrEL) and ethanol, was developed to address the solvent-related toxicities associated with conventional paclitaxel formulation. OBJECTIVE: To evaluate the efficacy and safety of NPLS versus CrEL-based paclitaxel (conventional paclitaxel) in patients with metastatic breast cancer (MBC). DESIGN: A prospective, open-label, randomized, multiple-dose, parallel, phase II/III study...
2024: Therapeutic Advances in Medical Oncology